- Global Pharma News & Resources

Aquestive Therapeutics Names Lori J. Braender, Esq. as Senior Vice President, General Counsel

Aquestive Therapeutics Names Lori J. Braender, Esq. as Senior Vice President, General Counsel

PR Newswire

WARREN, N.J., Sept. 11, 2018

WARREN, N.J., Sept. 11, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced that Lori J. Braender, Esq. will join the company as Senior Vice President, General Counsel effective as of September 10.

"We are pleased to welcome Lori," said Keith J. Kendall, Chief Executive Officer of Aquestive Therapeutics. "With her knowledge and familiarity of the company, and the depth of her professional experience, Lori will be an important part of the leadership of Aquestive."

Braender joins Aquestive from a 35-year career at Day Pitney LLP, where she was most recently Chair of the Life Sciences Practice Group. In that role, she specialized in advising clients in pharmaceutical, biotechnology, medical device companies, hospitals and healthcare institutions on regulatory requirements, contractual arrangements, and other business considerations connected with life science and healthcare transactions.

Ms.Braender added, "I'm honored to join the Aquestive team. The company's unique business model and technology deliver meaningful solutions to patients, and I Iook forward to contributing the success of these efforts."

About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm┬« technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "project," "will," "would," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements.  Such statements include, but are not limited to, statements about regulatory approvals and pathways, clinical trial timing and plans, the achievement of clinical and commercial milestones, future financial and operating results, business strategies, market opportunities, financing, and other statements that are not historical facts.

These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials; the risks of delays in FDA approval of our drug candidates or failure to receive approval; the risks inherent in commercializing a new product (including technology risks, financial risks,market risks and implementation risks and regulatory limitations); development of our sales and marketing capabilities; the rate and degree of market acceptance of our product candidates; the success of any competing products; the size and growth of our product markets; the effectiveness and safety of our product candidates; risks associated with intellectual property rights and infringement; unexpected patent developments; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in our Registration Statement on Form S-1 declared effective by the SEC on July 24, 2018. As with any pharmaceutical product candidate underdevelopment, there are significant risks with respect to the development, regulatory approval and commercialization of new products. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. We assume no obligation to update our forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Media inquiries:
Christopher Hippolyte

Investor inquiries:
Stephanie Carrington

View original content to download multimedia:

SOURCE Aquestive Therapeutics

Editor Details

Last Updated: 11-Sep-2018